BGI Bid to Acquire Complete Genomics Passes US Antitrust Hurdle; Tender Offer Extended Again | GenomeWeb

NEW YORK (GenomeWeb News) – BGI-Shenzhen and Complete Genomics said today that their proposed merger has cleared US antitrust review.

The companies said that they have received early termination of the Hart-Scott-Rodino waiting period from the Federal Trade Commission regarding BGI's $118 million bid for Complete.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.